Immunogenicity and Safety of a Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) Administered to Adults Aged 56 Years and Older: Results of an Open-Label, Randomized, Controlled Trial
The burden of invasive meningococcal disease is substantial in older adults in whom the case fatality rate is high. Travelers to regions with high rates of meningococcal disease, such as Hajj pilgrims, are at increased risk of meningococcal infection, and disease transmission from travelers to their close contacts has been documented. In younger individuals, meningococcal conjugate vaccines offer advantages over polysaccharide vaccines in terms of duration of protection and boostability, and induction of herd immune effects through reductions in nasopharyngeal carriage of meningococci. To date, few data are available evaluating meningococcal conjugate vaccine use in adults >55 years of age.
To evaluate the immunogenicity and safety of quadrivalent meningococcal serogroups A, C, W-135 and Y vaccine with all serogroups conjugated to tetanus toxoid (MenACWY-TT, Nimenrix™, GlaxoSmithKline, Belgium) and a licensed quadrivalent polysaccharide vaccine (MenPS, Mencevax™ GlaxoSmithKline, Belgium) in adults >55 years of age.
This was a phase IIIb, open-label, randomized (3:1), controlled study conducted at one study center in Lebanon. A total of 400 healthy adults between 56 and 103 years of age without previous MenPS or tetanus toxoid vaccination within the previous 5 years or meningococcal conjugate vaccination at any time previously were included. They received a single-dose vaccination with MenACWY-TT or MenPS with blood sampling before and 1 month after vaccination. The main outcome measures were serum bactericidal activity (rabbit complement source: rSBA) vaccine response (VR) rate [rSBA titer of ≥1:32 in initially seronegative subjects (rSBA titer <1:8); ≥4-fold increase in subjects with pre-vaccination rSBA titers between 1:8 and 1:128, and ≥2-fold increase in subjects with pre-vaccination rSBA titers ≥1:128]. The percentages of subjects with rSBA titers ≥1:8 and ≥1:128 and rSBA geometric mean titers (GMTs) were assessed. Solicited adverse events were recorded for 4 days following vaccination, and all other adverse events, including the incidence of new onset chronic diseases, were recorded for 31 days after vaccination.
One month after a single dose of MenACWY-TT, the rSBA VR rate in the MenACWY-TT group was 76.6 % for serogroup A, 80.3 % for serogroup C, 77.5 % for serogroup W-135 and 81.9 % for serogroup Y. VR rates in the MenPS group were 91.7, 84.8, 87.1 and 89.1 %, respectively. One month after vaccination, ≥93.2 % of subjects in the MenACWY-TT group and ≥93.9 % in the MenPS group had rSBA titers ≥1:128. In each group, GMTs increased by ≥13-fold for each serogroup. rSBA VR and GMTs tended to be lower in subjects who were over 65 years compared to 56–65 years of age. Only 6.3 % of MenACWY-TT recipients had anti-TT ≥0.1 IU/ml prior to vaccination, increasing to 28.1 % post-vaccination. The rSBA GMTs were 1.9- to 4-fold higher in anti-TT responders. Each local and general solicited symptom was reported by no more than 3.0 % of subjects in either group. No serious adverse events were considered vaccine related.
In adults 56 years of age and older, MenACWY-TT was immunogenic, with a vaccine response rate ≥76 % and with ≥93 % of subjects achieving rSBA titers ≥1:128 against all four serogroups after a single dose. MenACWY-TT induced low anti-TT concentrations in this population, which deserves further study.
- Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J. 2004;23(12 Suppl):S274–279.
- Cohn, AC, MacNeil, JR, Harrison, LH (2010) Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin Infect Dis 50: pp. 184-191 CrossRef
- Australian Meningococcal Surveillance Programme. Australian Meningococcal Surveillance Programme annual report, 2010. Commun Dis Intell. 2011;35(3):217–28.
- Gray, SJ, Trotter, CL, Ramsay, ME (2006) Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 55: pp. 887-896 CrossRef
- Harrison, LH, Trotter, CL, Ramsay, ME (2009) Global epidemiology of meningococcal disease. Vaccine 24: pp. B51-B63 CrossRef
- Gagneux, SP, Hodgson, A, Smith, TA (2002) Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J Infect Dis 185: pp. 618-626 CrossRef
- Boisier, P, Nicolas, P, Djibo, S (2007) Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 44: pp. 657-663 CrossRef
- Decosas, J, Koama, J-BT (2002) Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. Lancet Infect Dis 2: pp. 763-765 CrossRef
- Collard, JM, Maman, Z, Yacouba, H (2010) Increase in Neisseria meningitidis serogroup W135, Niger, 2010. Emerg Infect Dis 16: pp. 1496-1498 CrossRef
- Memish, ZA, Goubeaud, A, Bröker, M (2010) Invasive meningococcal disease and travel. J Infect Public Health 3: pp. 143-151 CrossRef
- Wilder-Smith, A, Goh, KT, Barkham, T (2003) Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis 36: pp. 679-683 CrossRef
- Aguilera, J-F, Perrocheau, A, Meffre, C (2002) Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg Infect Dis 8: pp. 761-767 CrossRef
- Parent du Chatelet, I, Barboza, P, Taha, M (2012) W135 invasive meningococcal infections imported from Sub-Saharan Africa to France, January to April 2012. Euro Surveill 17: pp. 1-2
- Saudi Ministry of Health Requirements - Hajj. 2012 Jan 9 [online]. Available from URL: http://www.hajinformation.com/main/p3001.htm.
- Harrison, LH (2006) Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 19: pp. 142-164 CrossRef
- Poolman, J, Borrow, R (2011) Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 10: pp. 307-322 CrossRef
- Granoff, DM, Gupta, RK, Belshe, RB (1998) Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 178: pp. 870-874 CrossRef
- Auckland, C, Gray, S, Borrow, R (2006) Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 194: pp. 1745-1752 CrossRef
- Trotter, CL, Maiden, MCJ (2009) Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 8: pp. 851-861 CrossRef
- Stamboulian, D, Lopardo, G, Lopez, P (2010) Safety and immunogenicity of an investigational quadrivalent meningococcal CRM (197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America. Int J Infect Dis 14: pp. e868-e875 CrossRef
- Dbaibo G, Macalalad N, Reyes MRA-DL, et al. The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study. Hum Vaccin Immunother 2012;8(7):873–80.
- Reyes MRA-DL, Dimaano E, Macalalad N, et al. The investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults. Hum Vaccin Immunother. 2012;8 (7):881–7.
- Nimenrix. Meningococcal group A, C, W 135 and Y conjugate vaccine. European Medicines Agency. 2012. 2012 Jun 22 [online]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002226/human_med_001548.jsp&mid=WC0b01ac058001d124.
- Ostergaard, L, Lebacq, E, Poolman, J (2009) Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years. Vaccine 27: pp. 161-168 CrossRef
- Knuf, M, Kieninger-Baum, D, Habermehl, P (2010) A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 28: pp. 744-753 CrossRef
- Baxter, R, Baine, Y, Ensor, K (2011) Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr Infect Dis J 30: pp. e41-e48 CrossRef
- Vesikari, T, Karvonen, A, Bianco, V (2011) Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: an open, randomized controlled trial. Vaccine 29: pp. 4274-4284 CrossRef
- Memish, ZA, Dbaibo, G, Montellano, M (2011) Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr Infect Dis J 30: pp. e56-e62 CrossRef
- Knuf, M, Pantazi-Chatzikonstantinou, A, Pfletschinger, U (2011) An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with InfanrixTM hexa is immunogenic, with an acceptable safety profile in 12–23-month-old children. Vaccine 29: pp. 4264-4273 CrossRef
- Bermal, N, Huang, L-M, Dubey, A (2011) Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccine 7: pp. 239-247 CrossRef
- Maslanka, SE, Gheesling, LL, Libutti, DE (1997) Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 4: pp. 156-167
- Borrow, R, Balmer, P, Miller, E (2005) Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine 23: pp. 2222-2227 CrossRef
- Andrews, N, Borrow, R, Miller, E (2003) Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 10: pp. 780-786
- Melville-Smith, ME, Seagroatt, VA, Watkins, JT (1983) A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand 11: pp. 137-144 CrossRef
- Jokhdar, H, Borrow, R, Sultan, A (2004) Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin Diagn Lab Immunol 11: pp. 83-88
- Keyserling, H, Papa, T, Koranyi, K (2005) Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 159: pp. 907-913 CrossRef
- Al-Mazrou, Y, Khalil, M, Findlow, H (2012) Immunogenicity and safety of a meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with one dose of bivalent and quadrivalent meningococcal polysaccharide vaccine: phase III, controlled, randomized, modified blind-observer study. Clin Vaccine Immunol 19: pp. 999-1004 CrossRef
- Dbaibo, G, Wielen, M, Reda, M (2012) The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine. Int J Infect Dis. 16: pp. e608-6 CrossRef
- United Nations Population Division. World population prospects: the 2010 revisions population database. 2011 [online]. Available from: http://esa.un.org/unpd/wpp/unpp/panel_indicators.htm.
- Dagan, R, Poolman, J, Siegrist, C-A (2010) Glycoconjugate vaccines and immune interference: a review. Vaccine 28: pp. 5513-5523 CrossRef
- Karabay, O, Ozkardes, F, Tamer, A, Karaarslan, K (2005) Tetanus immunity in nursing home residents of Bolu, Turkey. BMC Public Health 12: pp. 5 CrossRef
- Redwan, E-RM, Al-Awady, MK (2002) Prevalence of tetanus immunity in the Egyptian population. Hum Antibodies 11: pp. 55-59
- Cilla, G, Sáenz-Domínguez, JR, Montes, M, Part, C, Pérez-Trallero, E (1994) Immunity against tetanus in adults over the age of 49 years. Med Clin 103: pp. 571-573
- Theeten, H, Rümke, H, Hoppener, FJP (2007) Primary vaccination of adults with reduced antigen-content diphtheria-tetanus-acellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria-tetanus-toxoid vaccines. Curr Med Res Opin 23: pp. 2729-2739 CrossRef
- Damme, P, McIntyre, P, Grimprel, E (2011) Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trials. Vaccine 29: pp. 5932-5939 CrossRef
- Immunogenicity and Safety of a Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) Administered to Adults Aged 56 Years and Older: Results of an Open-Label, Randomized, Controlled Trial
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Drugs & Aging
Volume 30, Issue 5 , pp 309-319
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing AG
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. The Center for Infectious Diseases Research and the Department of Pediatrics and Adolescent Medicine, American University of Beirut, P.O. Box: 11-0236, Riad El Solh, Beirut, 1107 2020, Lebanon
- 2. GlaxoSmithKline Vaccines, Wavre, Belgium
- 3. GlaxoSmithKline Vaccines, King of Prussia, PA, USA